Screener
Kura Oncology KURA Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | 12,499 | 14,108 |
| Total revenue | 18,265 | 14,108 |
| Operating Expenses | ||
| Cost of product sales | 262 | — |
| Research and development | 65,263 | 55,973 |
| Selling, general and administrative | 31,555 | 22,835 |
| Total operating expenses | 97,080 | 78,808 |
| Loss from operations | (78,815) | (64,700) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's total cost of revenue?
- Kura Oncology (KURA) reported total cost of revenue of $262K in Q1 2026.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Kura Oncology's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude